Clinical Trial of Siddha Medicine Nandhi Mezhugu in the Treatment of Breast Cancer

Clinical Trial to Evaluate the Safety and Efficacy of Siddha Medicine Nandhi Mezhugu in Stage 1 and 2 Breast Cancer Patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/10/037630

Enrollment

Registered

2021-10-27

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast Health Condition 2: C500- Malignant neoplasm of nipple and areola Health Condition 3: C500- Malignant neoplasm of nipple and areola

Interventions

Intervention1: NANDHI MEZHUGU: 500 mg, with Palm Jaggery, BD for 40 days Control Intervention1: Nil: Nil Control Intervention2: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: 1. Female patients in the age group of 18- 60 years 2. Patients with histologically/cytologically confirmed carcinoma of the breast of stages I & II. 3. Patient willing to take siddha medicine 4. Patients ready to consent and to abide to trial related procedures

Exclusion criteria

Exclusion criteria: 1. Patient willing to take chemotherapy/radiotherapy/ undergo surgery/ any other alternative medicines 2. Patients who have received prior chemotherapy/ hormonal therapy/ investigational drugs/ alternative therapies for the treatment of breast cancer within last 1 month 3. Patients who have under gone surgery for stage I & II breast cancer 4. Patients with stage III and IV (who are with distant metastasis at diagnosis) 5. Patients with severe illness 6. Patients with significant existing breast trauma 7. Patients with abnormal renal & liver functions 8. Confirmed diagnosis of HIV or Hepatitis B/C 9. Inability to comply with the study protocol 10. Pre-menopausal female patients who are pregnant, lactating or of reproductive potential and not employing effective birth control measures

Design outcomes

Primary

Measure	Time frame
?Radiological objective response to the treatment (Using imaging studies) ?To establish the safety of Nandhi Mezhugu after treatment Timepoint: oth day, 56th day oth day, 56th day	—

Secondary

Measure	Time frame
Changes in Health related Quality of Life (EORTC QLQ-BR23) Tumor marker assessment before during & after treatment Timepoint: 0th day, 56th day 0th day, 26th day, 56th day	—

Countries

India

Contacts

Public ContactDr VG Huddar

Central Council for Research in Siddha

drakila10@gmail.com7208152857

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026